NASDAQ: NVCT - Nuvectis Pharma, Inc.

Yield per half year: +53.42%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Nuvectis Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives.

more details
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2022-02-04
ISIN US67080T1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.nuvectis.com
Цена ао 8.75
Change price per day: 0% (9.65)
Change price per week: -5.39% (10.2)
Change price per month: +40.67% (6.86)
Change price per 3 month: +84.87% (5.22)
Change price per half year: +53.42% (6.29)
Change price per year: +17.68% (8.2)
Change price per 3 year: +28.67% (7.5)
Change price per year to date: +107.53% (4.65)
All parameters

Underestimation

Title Value Grade
P/S 622.09 1
P/BV 9.53 1
P/E 0 0
EV/EBITDA -4.8 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -100.55 0
ROE, % -173.41 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 228870 10
Yield EPS, % 141153.95 10
Total: 6
More

Institutions Volume Share, %
Blackrock Inc. 387891 2.18
Vanguard Group Inc 294283 1.66
Baldwin Brothers, Inc. 142040 0.8
Geode Capital Management, LLC 131657 0.74
State Street Corporation 118279 0.67
Northern Trust Corporation 61574 0.35
Renaissance Technologies, LLC 51800 0.29
Millennium Management LLC 34011 0.19
Forbes, J.M. & Company 34000 0.19
GSA Capital Partners LLP 27313 0.15

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.0153 17.09 1.54048
0.0217.091.54



Head Job title Payment Year of birth
Mr. Ron Bentsur M.B.A. Co-Founder, Chairman, CEO & President 1.12M 1966 (59 years)
Dr. Enrique Poradosu Ph.D. Co-Founder, Executive VP, Chief Scientific & Business Officer 705.5k 1967 (58 years)
Mr. Shay Shemesh Co-Founder, Executive VP, Chief Development & Operations Officer 705.5k 1984 (41 year)
Mr. Michael Carson CPA Vice President of Finance N/A 1976 (49 years)

Address: United States, Fort Lee. NJ, 1 Bridge Plaza - open in Google maps, open in Yandex maps
Website: https://www.nuvectis.com